LAUSR

BACKGROUND The relationship between the activation of the renin-angiotensin system and the increase in erythropoiesis has been shown in many studies. In addition, the use of angiotensin converting enzyme inhibitors or angiotensin-receptor blockers has been reported to reduce hemoglobin levels in various patient groups at risk for secondary erythrocytosis/polycythemia. AIMS To investigate whether there is any change in hemoglobin levels after starting ACEI or ARB in patients who have not previously used them. METHODS 351 patients who were started on RAAS blockers were evaluated retrospectively. None of the patients had anemia before starting RAAS blockers. A median of 6 (4-12) months after the start of the drug, complete blood count and kidney function tests were evaluated. Hemoglobin values before and after the start of the drug were compared statistically. RESULTS A statistically significant decrease in mean Hb value was found after starting ACEI or ARB (14.39±1.29 g/dl vs. 13.98±1.36 g/dl, p<0.001). The decrease in control Hb values was higher in the ARB group than in the ACEI group (-0.53±0.06 g/dl vs -0.29±0.06 g/dl, p<0.001). CONCLUSIONS A significant decrease in mean Hb level was detected in the first year following the first administration of ACEIs or ARBs.